October 5, 2023 03:29 PM EDTUpdated 04:18 PM

FDA's oncology adcomm votes against Amgen's confirmatory data for Lumakras in certain types of NSCLC

Zachary Brennan

Senior Editor

The FDA and its oncology advisory committee raised lots of questions on whether Amgen’s confirmatory trial is enough to convert an accelerated approval to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's oncology adcomm votes against Amgen's confirmatory data for Lumakras in certain types of NSCLC

Zachary Brennan

Senior Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA's on­col­o­gy ad­comm votes against Am­gen's con­fir­ma­to­ry da­ta for Lumakras in cer­tain types of NSCLC

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA's oncology adcomm votes against Amgen's confirmatory data for Lumakras in certain types of NSCLC

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings